Zacks: Shockwave Medical Inc (NASDAQ:SWAV) Given $45.67 Consensus Target Price by Analysts
Shockwave Medical Inc (NASDAQ:SWAV) has been assigned an average broker rating score of 3.00 (Hold) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a hold recommendation.
Analysts have set a twelve-month consensus price target of $45.67 for the company and are anticipating that the company will post ($0.52) EPS for the current quarter, according to Zacks. Zacks has also assigned Shockwave Medical an industry rank of 83 out of 256 based on the ratings given to its competitors.
A number of equities research analysts have weighed in on SWAV shares. Zacks Investment Research lowered Shockwave Medical from a “hold” rating to a “sell” rating in a report on Tuesday, July 9th. Canaccord Genuity lifted their price objective on Shockwave Medical from $50.00 to $65.00 and gave the company a “positive” rating in a report on Tuesday, June 18th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $44.00 price objective on shares of Shockwave Medical in a report on Thursday, June 13th.
Shares of NASDAQ SWAV traded down $1.52 during midday trading on Monday, reaching $41.05. 198,240 shares of the company were exchanged, compared to its average volume of 395,649. The company has a quick ratio of 8.59, a current ratio of 9.13 and a debt-to-equity ratio of 0.10. Shockwave Medical has a 1 year low of $24.58 and a 1 year high of $68.39. The company’s fifty day moving average is $48.22.
Shockwave Medical (NASDAQ:SWAV) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.17. The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $8.29 million. Shockwave Medical’s quarterly revenue was up 334.8% compared to the same quarter last year. As a group, analysts anticipate that Shockwave Medical will post -2.51 earnings per share for the current year.
About Shockwave Medical
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Recommended Story: How a Put Option Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.